“Companies Are Bought, Not Sold.”

On April 27, Biosparc, RA Capital Management and True Light Capital jointly hosted “A Dialogue with RA Capital: Innovation Paradigms and Cross-Border Growth” in Suzhou Industrial Park.

During the event, Rajeev Shah, Managing Partner, RA Capital Management, focused not on emerging technology trends, fundraising conditions, or the next wave of innovation, but on a more fundamental question:

How should biotech companies think about value creation, and how is that value built over time?

According to Shah, one of the defining characteristics of the biotech industry is that value creation cannot be measured on a short timeline. Drug development is inherently high-risk, capital-intensive, and characterized by long development cycles. In many cases, a company’s greatest challenge is not the underlying science itself, but the tendency to adopt a transaction mindset before meaningful value has truly been established.

 

Drug Development Is Not Linear—It Is a High-Risk Climb

To illustrate this point, Shah shared a simple but powerful analogy.

In his view, drug innovation resembles a long and uncertain mountain climb. Foundational science, research infrastructure, and the broader innovation ecosystem form the base camp. What ultimately drives the industry forward is the potential reward created by successful medicines reaching patients.

The analogy reflects the fundamental economics of biotechnology. Drug development is not a linear industrial process. It requires patient capital, continuous experimentation, and the ability to navigate significant uncertainty over extended periods of time.

Scientific breakthroughs alone are not enough. Sustained investment from long-term capital providers remains essential to advancing innovation through the inevitable challenges of development.

Shah noted that the United States has maintained its position at the center of the global biotechnology ecosystem in part because it continues to offer one of the most attractive environments for rewarding successful innovation.

At the same time, he emphasized that modern biotech innovation increasingly depends on collaboration across multiple geographies. Different countries and ecosystems contribute distinct capabilities throughout the development process, and China is becoming an increasingly important part of that global framework.

Many of the discussions during the event—from cross-border collaboration and global development strategies to company creation and venture building—were rooted in this broader context.

 

“Companies Are Bought, Not Sold.”

One of the most memorable messages from Shah’s presentation was a simple statement:

“Companies are bought, not sold.”

According to Shah, many biotech companies begin optimizing too early for transactions. They pursue business development opportunities solely for the sake of doing deals, shape their strategies around potential acquirers, or adjust development priorities in anticipation of a future sale.

The strongest companies, however, take a different approach.

“Build your company as if it will remain independent forever.”

When a company creates genuine standalone value, strategic transactions tend to occur naturally. High-quality assets are rarely sold through aggressive positioning; instead, they attract interest because the market recognizes their value and competes to acquire them.

Drawing on RA Capital’s experience in company building, venture creation, and M&A transactions, Shah explained that the firm has participated in acquisitions involving more than 65 portfolio companies and has completed transactions with 36 different pharmaceutical companies.

Across these experiences, one lesson has consistently emerged:

Successful outcomes are rarely determined by negotiation tactics alone. What matters most is how effectively a company creates, demonstrates, and communicates value over time.

 

Understanding the Value Inflection Point

Shah emphasized the importance of identifying what he described as a company’s “value inflection point.”

In many cases, transformational value is not created by a scientific concept alone, but by the successful validation of a critical milestone. That milestone may be a clinical data readout, proof-of-mechanism evidence, or first-in-human results.

Once such milestones are achieved, market perception can change rapidly.

Many companies, however, enter transaction discussions while uncertainty remains high and before these defining moments have occurred.

To illustrate this challenge, Shah offered another memorable piece of advice:

“Don’t transact the night before dawn.”

The statement captures a core principle of RA Capital’s company-building philosophy: helping companies reach the milestones that fundamentally change how their value is perceived, rather than pursuing exits before that value has fully emerged.

 

From Being Overlooked to Being Recognized

To further illustrate how value is created over time, Shah shared several examples from RA Capital’s experience.

One case involved an influenza-related asset that had been deprioritized following strategic shifts within a large pharmaceutical company. As additional clinical data emerged, market perception of the asset gradually evolved.

For RA Capital, the priority was not completing a transaction as quickly as possible, but supporting continued development while helping the market better understand the asset’s long-term potential.

According to Shah, the most important aspect of these stories is not the final transaction value. It is the process by which companies advance their assets toward milestones capable of fundamentally changing market perception.

Throughout that process, RA Capital works closely with companies to engage potential pharmaceutical partners, continuously refine strategic positioning, and build market understanding around the asset’s value proposition.

Indeed, a recurring theme throughout Shah’s presentation was the importance of creating genuine standalone value, identifying meaningful value inflection points, and maintaining long-term market education and positioning efforts.

 

The Real Scarcity in Biotech

For many years, biotechnology companies were often defined primarily by technological breakthroughs.

Today, however, the increasing complexity of drug development means that long-term success depends on much more than science alone.

Companies must be able to advance technology through clinical development, establish viable regulatory and commercialization pathways, build market confidence, and navigate uncertainty over extended periods of time.

According to Shah, asset value is rarely self-evident.

In many cases, the greatest risk facing a biotech company is not scientific failure, but entering into transactions before its value has fully emerged and before it has established sufficient leverage.

As a co-host of the event, Biosparc remains committed to advancing international life sciences innovation and connecting Chinese innovators with global industry, capital, and research communities.

Its collaboration with RA Capital and True Light Capital represents a practical example of that mission—providing Chinese biotech companies with a unique opportunity to better understand how leading global investors think about value creation and company building.

In today’s global biotech industry, what may be truly scarce is no longer technology alone, but the ability to transform technology into enduring value.